Spondyloarthropathy

ORLANDO, Fla. — Understanding the nuances of spondyloarthropathy diagnostic criteria can help prevent “debilitating” consequences, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

As many as 96% of patients with axial spondyloarthritis who withdrew from ixekizumab after a favorable response were able to recapture low disease activity, while 71% retained inactive disease, after resuming the drug, according to data.

Patients with axial spondyloarthritis demonstrate significant differences in peripheral and extra-musculoskeletal manifestations based on geographic region, according to data published in Rheumatology.

Nonradiographic axial spondyloarthritis remains an underrecognized and undertreated condition in the United States, with rheumatology often the last stop for many of these patients. However, with a recent ICD-10 code upgrade, that may begin to change.

Bimekizumab demonstrates statistically significant improvement over placebo in the proportion of patients achieving Assessment of Spondyloarthritis International Society 40 response at week 16, according to interim results released by UCB.

Given the limited awareness of non-radiographic axial spondyloarthritis, differentiating this disease from radiographic disease and prescribing appropriate therapy remains a key challenge, according to a presentation at the Biologic Therapies Summit.

Twitter use revealed “early signals” of drug rationing and other critical behavior changes in patients with rheumatic diseases as they navigated the early months of the COVID-19 pandemic, according to data published in Rheumatology.

During the early months of the COVID-19 pandemic, increased all-cause mortality in patients with rheumatoid arthritis and other inflammatory joint diseases largely mirrored that of the general population, according to data.